Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 11, 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 860,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,179.98 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.13% of total voting rights).
- Shares in Issue: 5,192,238,653 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's share capital through the cancellation of 860,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 474,194,158, while the number of shares in issue remains 5,192,238,653.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming the execution of a share buyback and the resulting capital structure.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (860,000 shares at 1,179.98 pence) against the Company's cash position in other filings.
- Confirm the updated Treasury share count of 474,194,158 and its impact on earnings per share calculations.
- Note that the 5,192,238,653 shares in issue serve as the denominator for Disclosure and Transparency Rule notifications.